[ad_1]
Beximco Pharmaceuticals Limited (BPL) has signed a Memorandum of Understanding (MoU) with the Serum Institute of India (SII) to assist in the development and distribution of coronavirus vaccines.
Beximco Pharmaceuticals said in a statement on Friday that it would act as “one of the main suppliers” of the vaccine in Bangladesh.
The Serum Institute of India, a joint venture between the UK’s AstraZeneca Company, the Gates Foundation and the Global Vaccine Alliance (GAVI), has been involved in the development of more than 1 billion corona vaccines for global supply.
Beximco said it would finance Serum by adjusting the price of the vaccine under the terms of the agreement.
Beximco also said that if the vaccine is approved in the world market, Bangladesh will have priority to obtain it.
The statement said that Beximco would work to ensure the needs of the Bangladeshi government. Beximco will have the opportunity to stock and supply vaccines on demand at a price agreed between the Government of Bangladesh and the SII.
Beximco will also guarantee the supply of vaccines in the open market of Bangladesh, according to the statement.
SII Executive Director Adar C Punawala and BPL Director Shayan F Rahman said in a joint statement: “Together, as representatives of the two countries, we will go a long way to resolve the crisis caused by the Kovid epidemic. -19 “.
